title: GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients.
abstract: OBJECTIVE
  To determine the protective effect of gonadotropin-releasing hormone analogs (GnRHa) using several ultrasound and endocrine markers to detect ultrastructural ovarian damage in Hodgkin's lymphoma patients.
  
  
  METHODS
  Ten patients who had been treated for Hodgkin's lymphoma and had received GnRHa to protect ovarian function were matched with patients at similar age, who had received the same chemotherapy regimens without GnRHa. In addition, ten healthy women at the same age were matched to the study groups to compare ovarian markers. Blood samples were drawn to determine anti-Müllerian hormone, Inhibin B, follicle-stimulating hormone and transvaginal ultrasound scans were performed to determine antral follicle count and ovarian volume. All women were asked about their menstrual cycle pattern.
  
  
  RESULTS
  No difference was found when comparing the ovarian parameters of both study groups. Compared with healthy women, all ovarian parameters in the Hodgkin's lymphoma patients were significantly different.
  
  
  CONCLUSIONS
  The results of this study demonstrate ultrastructural ovarian damage in Hodgkin's lymphoma patients irrespective of GnRHa co-treatment. These findings do not support previous studies, showing GnRHa to protect ovarian function.
authors.affiliation: Department of Gynecological Endocrinology and Reproductive Medicine, Woman's University Hospital of Bern, Effingerstrasse 102, Bern, Switzerland.
authors.forename: Markus
authors.initials: M
authors.lastname: Nitzschke
authors.forename: Juliane
authors.initials: J
authors.lastname: Raddatz
authors.forename: Michael K
authors.initials: MK
authors.lastname: Bohlmann
authors.forename: Petra
authors.initials: P
authors.lastname: Stute
authors.forename: Thomas
authors.initials: T
authors.lastname: Strowitzki
authors.forename: Michael
authors.initials: M
authors.lastname: von Wolff
mesh_terms: D000293:Adolescent; D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000494:pharmacology; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D007265:Inhibins / Q000097:blood; D010049:Ovarian Diseases / Q000097:blood / Q000139:chemically induced*; D010053:Ovary / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D016649:Primary Ovarian Insufficiency / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D014463:Ultrasonography; D055815:Young Adult
chemical_list: C422364:inhibin B; D007987:Gonadotropin-Releasing Hormone; D007265:Inhibins; D054304:Anti-Mullerian Hormone; D005640:Follicle Stimulating Hormone